Kevin R.M. Smith

Chief Executive Officer at Inogen Inc

Board

Since November 10, 2023

Age

54 years

Education

Holds a Master of Business Administration (MBA) in Global Management from the University of Phoenix and a Bachelor of Science (B.S.) in Marketing from the University of Kentucky.

Tenure

Joined INGN on November 10, 2023, as Chief Executive Officer, President, and Director, succeeding the previous leadership.

Also at Inogen Inc

Gregoire Ramade

Executive Vice President, Chief Commercial Officer

Michael Bourque

Executive Vice President, Chief Financial Officer, and Corporate Treasurer

About

Kevin R.M. Smith is a seasoned executive with extensive experience in the medical device and biotechnology industries, having held several senior leadership roles over the past two decades.

He advanced his career through roles at various organizations, including serving as Executive Vice President of Sales & Marketing at Sirtex Medical Limited and as Interim President and CEO at OncoSec Medical, Inc., among others.

At INGN, he joined on November 10, 2023, and assumed the roles of Chief Executive Officer, President, and Director, where he is tasked with driving the company’s growth and operational strategy.

His background is further complemented by his academic achievements, holding an MBA in Global Management and a BS in Marketing, which have underpinned his success in transforming businesses and leading global expansions.

$INGN Performance Under Kevin R.M. Smith

Past Roles

Organization	Role	Date Range	Details
Sirtex Medical Limited	CEO, President, and Executive Director	April 2019 to November 2023	Promoted from previous role; also provided executive leadership
OncoSec Medical, Inc.	Interim President, CEO and Director	December 2021 to April 2022	Also served on the Board of Directors from 2020 to 2023
Sirtex Medical Limited	Executive Vice President of Sales & Marketing, Americas	2017 to 2019	Role transitioned prior to CEO appointment
Gel-e, Inc.	Executive Vice President of Business Development	N/A [N/A]	N/A
Sensium Healthcare	Chief Commercial Officer	N/A [N/A]	N/A
Teleflex	Global Vice President of Sales & Marketing	N/A [N/A]	N/A

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Salary	$700,000	Annual	Base Salary
Bonus	$850,000	Annual	Cash Bonus
Time-Based RSUs	$597,125; 85,000 RSUs	3-year Vesting	Vests in one-third increments: first vesting on March 1, 2024 then annually
All Other Compensation	$6,600	Annual	Includes benefits and perquisites; further details not specified

Performance Compensation

Data from FY 2024

Performance-Based RSUs

Metric	Details
Performance Metric	Relative Total Shareholder Return (TSR) vs. S&P 1000 Health Care Equipment Select Industry
Threshold	25th percentile for 50% of target RSUs
Target	50th percentile for 100% of target RSUs
Maximum	60th percentile for 120% of target RSUs
Vesting Schedule	Earned over 3 years; vesting occurs by linear interpolation; if change in control, vest immediately
Evaluation Period	Through December 31, 2026
Grant Date	April 4, 2024
Grant Date Fair Value	$589,900
Number of RSUs	85,000

Non-Equity Incentive Plan Compensation

Metric	Threshold	Target	Maximum	Actual Achievement	Weight
Revenue ($USD M)	$310.9 M	$327.2 M	$335.4 M	$335.7 M (200% achievement)	50%
Adjusted EBITDA ($USD M)	($19.5 M)	($18.6 M)	($15.5 M)	($4.9 M) (200% achievement)	50%

Detail	Information
Target Annual Cash Incentive	$700,000
Maximum Annual Cash Incentive	$1,400,000
Actual Annual Cash Incentive Paid	$1,410,000
Grant Date for Awards	February 14, 2024
Grant Date Fair Value (Stock Awards)	$1,187,025
Grant Date Stock Price	$9.17 per share (closing price on December 31, 2024)

This section consolidates the performance compensation details for 2024, including both the performance-based RSUs and the non-equity incentive plan components.